MorphoSys AG Company Update January 2017

MorphoSys AG updates on its platform for antibody and peptide-based therapeutics, highlighting 40+ academic and pharma collaborations with over 100 ongoing programs and 28 clinical candidates. The company emphasizes its innovative antibody platform, strong balance sheet, and lucrative milestone and royalty potential from its partner strategy.